Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine.
Watanabe Y., Mendonça L., Allen ER., Howe A., Lee M., Allen JD., Chawla H., Pulido D., Donnellan F., Davies H., Ulaszewska M., Belij-Rammerstorfer S., Morris S., Krebs A-S., Dejnirattisai W., Mongkolsapaya J., Supasa P., Screaton GR., Green CM., Lambe T., Zhang P., Gilbert SC., Crispin M.
Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibodies that they produce appropriately processed and assembled viral antigen that mimics that observed on the SARS-CoV-2 virus. Here, we describe the structure, conformation and glycosylation of the S protein derived from the adenovirus-vectored ChAdOx1 nCoV-19/AZD1222 vaccine. We demonstrate native-like post-translational processing and assembly, and reveal the expression of S proteins on the surface of cells adopting the trimeric prefusion conformation. The data presented here confirms the use of ChAdOx1 adenovirus vectors as a leading platform technology for SARS-CoV-2 vaccines.